CRS Berlin in the headlines 📢 Igyxos Initiates Phase 1 Clinical Trials for IGX12: A Breakthrough Treatment for Infertility

✨ CRS Berlin in the headlines! ✨ CRS Berlin location at TechnoCampus in Spandau was featured in the EIN Presswire newspaper.

At our Berlin study center, we are conducting a study in collaboration with Igyxos, a leading biopharmaceutical company specializing in infertility solutions. The goal of this study is to conduct phase I clinical trials on IGX12, a pioneering monoclonal antibody (mAb) with very strong and consistent pre-clinical results and the potential to revolutionize infertility treatment.

This publication serves as confirmation of our team’s progress and serves as motivation to continue advancing. We welcome those interested in learning more about our work. 👨‍⚕️ 👩‍⚕️

Click here to read the article: